DEMOGRAPHIC DISTRIBUTION AND ECONOMIC BURDEN OF PATIENTS DIAGNOSED WITH RHEUMATOID ARTHRITIS IN THE U.S. MEDICARE POPULATION

Author(s)

Li L1, Mao X2, Shrestha S1, Baser O3, Yuce H4, Wang L1
1STATinMED Research, Plano, TX, USA, 2University of Texas at Dallas and STATinMED Research, Plano, TX, USA, 3STATinMED Research, Columbia University, New York, NY, USA, 4City University of New York & STATinMED Research, New York, NY, USA

OBJECTIVES: To determine the demographic distribution and health care burden of patients diagnosed with rheumatoid arthritis (RA) using Medicare fee-for-service (FFS) data. METHODS: A retrospective analysis was performed using the 100% Medicare FFS datasets from October 1, 2008 through December 31, 2012. Patients diagnosed with RA were identified using International Classification of Diseases, 9th Revision, Clinical Modification diagnosis code 714, and the first diagnosis date was designated as the index date. All patients were required to have continuous medical and pharmacy benefits 1 year pre- (baseline period) and post-index date (follow-up period). Health care resource utilization and costs during the baseline and follow-up periods were calculated. RESULTS: Using Medicare FFS data, 112,550 RA patients were identified. The average age at diagnosis was 76 years, and 72.54% of patients were women and 83.94% were white. The most common baseline comorbidities were diabetes (35.48%), followed by chronic obstructive pulmonary disease (30.83%) and cerebrovascular disease (21.50%). During the follow-up period, 66.35% of patients had inpatient admissions, 49.01% had emergency room visits, 87.93% had outpatient office visits, 87.93% had outpatient visits and 61.67% had pharmacy visits and costs were, on average, $26,510, $256, $4,204, $4,460 and $6,249, respectively. The average total costs incurred by RA patients were $37,219. The five most commonly-prescribed medications prescribed to treat RA were prednisone (3.40%), levothyroxine sodium (2.63%), hydrocodone bit/acetaminophen (2.39%), furosemide (2.13%) and omeprazole (2.13%). CONCLUSIONS: RA patient demographic distributions and RA-related health care cost information was obtained and the most commonly prescribed medications to treat RA were identified.

Conference/Value in Health Info

2015-05, ISPOR 2015, Philadelphia, PA, USA

Value in Health, Vol. 18, No. 3 (May 2015)

Code

PMS38

Topic

Economic Evaluation

Topic Subcategory

Cost/Cost of Illness/Resource Use Studies, Cost-comparison, Effectiveness, Utility, Benefit Analysis

Disease

Musculoskeletal Disorders

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×